FDA Removes Outdated Risk Warnings from Three Additional Menopause Patches

Posted on November 04, 2026

Read Story

The U.S. Department of Health and Human Services (HHS), through the FDA, has approved updated safety labeling for three additional estradiol transdermal patch products: Minivelle®, Vivelle®, and Vivelle-Dot®. The changes remove older boxed warning language regarding breast cancer, cardiovascular disease, and probable dementia that regulators now consider outdated in the context of current evidence on menopausal hormone therapy (MHT).

This action builds on the FDA's February 2026 decision to update the labeling of six other menopausal hormone therapy products, continuing a broader effort to ensure that prescribing information reflects the latest scientific understanding of hormone therapy's risks and benefits.

In addition to the label updates, HHS announced ongoing efforts to improve access to menopausal hormone therapy by increasing manufacturing capacity and addressing supply shortages, particularly for estrogen patches. The agency reported that nearly 30 manufacturers have submitted proposed label revisions since FDA outreach began in late 2025, with reviews continuing.

The FDA also highlighted regulatory measures designed to improve access to estradiol products, including temporary flexibility for certain outsourcing facilities that compound estradiol-containing medications. However, this aspect of the policy remains controversial.

Menopause expert, Holly L. Thacker, MD, called the announcement a positive step for midlife women. She said the updated labeling helps correct misconceptions that have persisted since the Women's Health Initiative and may provide reassurance to women who are appropriate candidates for hormone therapy. Dr. Thacker also praised efforts to improve access to FDA-approved hormone therapies and address ongoing patch shortages.

Dr. Thacker emphasized several important clinical considerations:

• Transdermal estrogen may be particularly beneficial for women with certain medical conditions, including a history of blood clots, elevated triglycerides, or cardiovascular disease.
• Women with a uterus who use systemic estrogen require adequate endometrial protection with progesterone or a progestin.
• Transdermal natural progesterone should not be considered adequate endometrial protection.
• FDA-approved hormone products remain the preferred option when available because they provide greater consistency, quality control, and regulatory oversight than compounded preparations.

Overall, the latest label revisions represent another step toward modernizing menopause care by aligning product labeling with current evidence while improving access to treatment options for women experiencing menopausal symptoms.

Read the original article on healio.com.